Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MDGL
CUSIP87162T20
Phone484-380-9263
Debt
Debt-to-Equity RatioN/A
Current Ratio29.12
Quick Ratio29.12
Price-To-Earnings
Trailing P/E Ratio-114.67
Forward P/E Ratio-112.89
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$13.02 per share
Price / Book22.37
Profitability
EPS (Most Recent Fiscal Year)($2.54)
Net Income$-31,150,000.00
Net MarginsN/A
Return on Equity-26.52%
Return on Assets-24.88%
Miscellaneous
Employees8
Outstanding Shares14,250,000
Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions
What is Madrigal Pharmaceuticals' stock symbol?
Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."
How were Madrigal Pharmaceuticals' earnings last quarter?
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) issued its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.33. View Madrigal Pharmaceuticals' Earnings History.
What price target have analysts set for MDGL?
8 analysts have issued twelve-month price objectives for Madrigal Pharmaceuticals' shares. Their forecasts range from $281.00 to $400.00. On average, they expect Madrigal Pharmaceuticals' stock price to reach $318.00 in the next year. View Analyst Ratings for Madrigal Pharmaceuticals.
Who are some of Madrigal Pharmaceuticals' key competitors?
Some companies that are related to Madrigal Pharmaceuticals include GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), BeiGene (BGNE), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS) and Dr.Reddy's Laboratories (RDY).
Who are Madrigal Pharmaceuticals' key executives?
Madrigal Pharmaceuticals' management team includes the folowing people:
- Dr. Paul A. Friedman, Chairman, Pres & CEO (Age 75)
- Mr. Marc R. Schneebaum, Sr. VP & CFO (Age 64)
- Dr. Rebecca A. Taub, Founder, Exec. VP of R&D, Chief Medical Officer and Director (Age 66)
Has Madrigal Pharmaceuticals been receiving favorable news coverage?
News stories about MDGL stock have been trending somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Madrigal Pharmaceuticals earned a daily sentiment score of 0.01 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 46.76 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Madrigal Pharmaceuticals' major shareholders?
Madrigal Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Rock Springs Capital Management LP (2.28%), BlackRock Inc. (2.24%), Victory Capital Management Inc. (1.42%), Citadel Advisors LLC (1.34%), Millennium Management LLC (0.65%) and Northern Trust Corp (0.52%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc, Marc R Schneebaum, Rebecca Taub and Richard S Levy. View Institutional Ownership Trends for Madrigal Pharmaceuticals.
Which institutional investors are selling Madrigal Pharmaceuticals stock?
MDGL stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Point72 Asset Management L.P., Lord Abbett & CO. LLC, Rock Springs Capital Management LP, Victory Capital Management Inc., D.A. Davidson & CO. and Caxton Corp. Company insiders that have sold Madrigal Pharmaceuticals company stock in the last year include Bay City Capital Llc, Marc R Schneebaum and Rebecca Taub. View Insider Buying and Selling for Madrigal Pharmaceuticals.
Which institutional investors are buying Madrigal Pharmaceuticals stock?
MDGL stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Artal Group S.A., UBS Group AG, Nexthera Capital LP, JPMorgan Chase & Co., Barclays PLC and Eventide Asset Management LLC. View Insider Buying and Selling for Madrigal Pharmaceuticals.
How do I buy shares of Madrigal Pharmaceuticals?
Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Madrigal Pharmaceuticals' stock price today?
One share of MDGL stock can currently be purchased for approximately $291.25.
How big of a company is Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals has a market capitalization of $4.07 billion. The biopharmaceutical company earns $-31,150,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Madrigal Pharmaceuticals employs 8 workers across the globe.
How can I contact Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 484-380-9263 or via email at [email protected]
MarketBeat Community Rating for Madrigal Pharmaceuticals (MDGL)
MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote "Outperform" if you believe MDGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
